

NEUVIOR

Carbon Reduction Plan

Initial public plan for NEUVIOR Pharmaceuticals Ltd. This version sets out the reporting boundary, climate governance model, and carbon reduction measures currently in effect or planned for a UK-based, early-stage digital health company building PHARMORIS.

Legal entity	NEUVIOR Pharmaceuticals Ltd
Company number	SC857853
Issue date	10 April 2026
Review date	10 April 2027
Registered office	Clyde Offices, 2nd Floor, 48 West George Street, Glasgow, Scotland, G2 1BP
Current business focus	Digital health product development, research, governance and commercial operations associated with PHARMORIS

Why this document exists

This public document sets out NEUVIOR's climate commitment and the operational measures being taken to reduce emissions over time in a way that is proportionate to a UK-based, early-stage digital health company building the PHARMORIS platform.

1. Executive summary

Current status note

This is NEUVIOR's first public Carbon Reduction Plan. It establishes the company's net zero target, reporting boundary, climate governance, carbon reduction priorities, and data-improvement plan. Because NEUVIOR is an early-stage SME and is still completing its first full greenhouse gas inventory, this version focuses on a defensible operating plan and publication pathway rather than overstating the availability of quantified emissions data. When the first complete inventory cycle is finalised, the plan will be updated with published baseline and current emissions.

NEUVIOR Pharmaceuticals Ltd is building PHARMORIS, a governed medicines action platform for the NHS. In the current stage of the company, the most material climate issues are not heavy manufacturing or logistics; they are the emissions associated with cloud and digital infrastructure, purchased goods and professional services, business travel, employee commuting, workspaces under operational control, and the procurement decisions that shape the company's future footprint.

This plan is intentionally tailored to that operating reality. It focuses on what a small but ambitious digital health company can control now: setting a whole-company 2045 net zero commitment, improving emissions data quality quickly, avoiding needless growth in travel and energy intensity, building supplier discipline early, and ensuring that climate commitments mature alongside the business rather than lag behind it.

2. Organisational profile and reporting boundary

Field	Position for this plan
Reporting entity	NEUVIOR Pharmaceuticals Ltd
Entity level	Whole reporting entity (no separate global parent company is being used for this plan).
Organisational boundary	Operational control approach, to align with the GHG Protocol and support consistent reporting as the company grows.
Current geography	United Kingdom. NEUVIOR is currently a UK-based company; if operations expand internationally, the company will restate the inventory and maintain the same company-wide net zero commitment.
Current operating model	Software development, product design, data analysis, governance, founder/business development activity, and related administrative functions.
Not currently treated as material operating activities	Large-scale manufacturing, warehousing, distribution fleet operations, or directly operated clinical estates.

3. Expected material emissions sources

Emissions area	Why it matters for NEUVIOR now	Current data status
Scope 1	Potentially relevant if direct fuel combustion, refrigerants, or company-controlled vehicles arise. For the current operating model, these are expected to be low or nil, but they still remain in scope and must be formally assessed.	Formal quantified baseline in progress.
Scope 2	Relevant where NEUVIOR directly purchases electricity, heating, cooling or steam for premises under its control. In the current operating model this is expected to be low or limited, but it must be confirmed through inventory work.	Formal quantified baseline in progress.
Scope 3 - purchased goods and services	Material for a digital company using cloud, software, devices, professional services and external suppliers.	Priority category for initial mapping.
Scope 3 - business travel	Founder, team and partner travel can become disproportionately material in an early-stage company if not controlled.	Priority category for initial mapping.
Scope 3 - employee commuting	Relevant as the company grows, including any regular office attendance patterns.	Priority category for initial mapping.
Scope 3 - waste generated in operations	Usually smaller for a digital company, but still relevant for procurement and workspace choices.	Priority category for initial mapping.
Scope 3 - upstream and downstream transportation	Expected to be limited at current scale, but still relevant for devices, equipment and any physical goods moved on the company's behalf.	To be assessed and disclosed where relevant.

4. Net zero target architecture

Long-term target

NEUVIOR Pharmaceuticals Ltd commits to achieve net zero greenhouse gas emissions by 2045 across Scope 1, Scope 2 and all relevant Scope 3 emissions.

Target element	NEUVIOR position
Target year	2045
Scope coverage	Scope 1, Scope 2 and all relevant Scope 3 emissions.
Reduction philosophy	Absolute reduction first. Offsetting or neutralisation should only be considered for genuine residual emissions once reduction measures have been pursued seriously.
Reporting standard	GHG Protocol Corporate Standard and GHG Protocol Corporate Value Chain (Scope 3) Standard.
Future validation ambition	NEUVIOR intends to move toward target-validation readiness as data quality and company maturity improve, including assessment of the SBTi SME route.
Why 2045	To align more closely with NHS supplier direction and the NHS Carbon Footprint Plus ambition, rather than only meeting the minimum 2050 threshold.

5. Carbon reduction measures currently in effect or being embedded

- Virtual-first working model. Use digital collaboration and remote meetings by default where this does not reduce effectiveness.
- Travel hierarchy. Challenge unnecessary travel, prefer virtual meetings where practical, and prefer rail or lower-carbon travel options over short-haul air where feasible.
- Digital-first delivery. Reduce paper, printed collateral and physical mail by default, using electronic documents, signatures and cloud-based workflows.
- Prudent device and equipment procurement. Avoid unnecessary equipment purchases, extend device life where practical, and use responsible recycling or reuse routes for obsolete IT assets.
- Cloud and software efficiency. Challenge unnecessary compute growth, duplicated storage, and wasteful digital processing. Ask material cloud and software suppliers for sustainability information where available.
- No routine fossil-fuel fleet build-out. If a company fleet or long-term leased vehicles are introduced in future, zero-emission options will be the default position unless there is a clear operational reason otherwise.

- Low-carbon workspace discipline. For any future premises under NEUVIOR's direct control, energy efficiency and renewable-backed electricity will be preferred wherever reasonably available.
- Supplier sustainability discipline. Start sustainability and modern-slavery screening early for key suppliers rather than leaving it until the company is much larger.

6. 2026 to 2030 implementation plan

Timing	Action	KPI / proof signal
Q2 2026	Publish the Net Zero Commitment and this Carbon Reduction Plan on the website, clearly signposted from corporate pages.	Public URLs live; issue date and review date visible.
Q2-Q3 2026	Complete the first full organisational greenhouse gas inventory and publish the first quantified baseline and reporting-year emissions schedule.	Published emissions page covering Scope 1, Scope 2 and relevant Scope 3 categories.
Q2-Q4 2026	Implement a simple but formal travel log, commuting data capture approach, supplier register and cloud/provider sustainability register.	Named owners, data sources and quarterly review cadence established.
By end 2026	Review whether NEUVIOR is ready to enter the SBTi SME pathway and whether emissions verification work should begin in 2027.	Board/director decision and documented action plan.
2027	Publish the first annual update, strengthen supplier screening, and improve Scope 3 completeness beyond the minimum NHS subset.	Annual update published within 12 months; material suppliers profiled.
2028-2030	Move from basic reporting to stronger decarbonisation discipline, including renewable electricity choices for directly controlled premises if applicable, product/service hotspot analysis where relevant, and tighter procurement controls.	Maturing year-on-year data quality, better supplier evidence, and operational measures demonstrably in effect.

7. Data quality, reporting and publication plan

NHS England's supplier guidance makes clear that a Carbon Reduction Plan should include current emissions data, but it also recognises that SMEs may, in acceptable circumstances, publish the emissions data they have available together with an explanation of any gaps and the steps being taken to improve data quality. NEUVIOR is therefore taking a staged but transparent approach.

Reporting item	NEUVIOR publication approach
Base year	To be fixed when the first full inventory is completed. A base year no earlier than 2015 is generally considered good practice, but the practical base year for NEUVIOR will be tied to the first complete and reliable data set.
Reporting year	12-month reporting period to be stated explicitly in each annual update.

Reporting item	NEUVIOR publication approach
Emissions methodology	Use GHG Protocol organisational and operational boundary principles, with appropriate published emissions conversion factors and consistent assumptions.
Data gaps	Where data is not yet available or is immaterial, this will be stated transparently with a date-bound improvement action rather than hidden.
Publication cadence	At least annually, and sooner if a material change occurs in the operating model, physical estate, or emissions profile.
Website location	Public sustainability area with clear links to the commitment, the Carbon Reduction Plan, and future emissions disclosures.

8. Supply chain, product and operational maturity pathway

Because NEUVIOR is building a digital platform rather than a physical product line, the company's most important medium-term sustainability challenge is disciplined growth. The risk is not only carbon from today's tiny operation; it is allowing avoidable emissions to become embedded as the company scales. That is why the plan emphasises supplier mapping, procurement discipline, cloud efficiency, travel control and data quality now, rather than waiting until the business is larger.

NEUVIOR also intends to keep pace with NHS sustainability expectations relevant to digital and service suppliers. As NHS guidance on product and service carbon footprinting matures, the company will review whether hotspot analysis or other fit-for-purpose approaches should be applied to the PHARMORIS service model. It will also build modern-slavery and supplier-risk processes progressively, as expected by later Evergreen maturity levels.

What this plan does not overclaim

This document does not claim that NEUVIOR already has independently validated science-based targets, independently verified emissions, a completed Modern Slavery Assessment Tool score, or a Level 3 / Level 4 Evergreen position. It is intended to be a truthful public plan and governance artifact that supports those later milestones.

9. Governance, review and declaration

Responsibility for this plan sits with the director of NEUVIOR Pharmaceuticals Ltd. The plan will be reviewed at least annually and updated within 12 months of publication. Material changes, such as international expansion, a dedicated office or lab estate, company vehicles, significant procurement growth, or new physical product activities, will trigger an earlier update.

This plan has been prepared with reference to NHS England's Carbon Reduction Plan and Net Zero Commitment guidance, the Evergreen Sustainable Supplier Assessment

2026/27 guidance, the GHG Protocol reporting standards, and the SBTi net zero framework. It is intended to be proportionate to the current scale and operating profile of NEUVIOR Pharmaceuticals Ltd while remaining rigorous enough to support NHS-facing scrutiny.

Declaration

This Carbon Reduction Plan is issued on behalf of NEUVIOR Pharmaceuticals Ltd and is intended to support the company's public sustainability disclosures and NHS-facing supplier readiness.

Approved for publication by: Varun Cruz, Director

Company number: SC857853

Issue date: 10 April 2026

Review date: 10 April 2027

References and guidance used

NHS England, Carbon reduction plan and net zero commitment requirements for the procurement of NHS goods, services and works (Version 3, updated 11 December 2025).

NHS England, Evergreen Sustainable Supplier Assessment User Guide (April 2026) and maturity matrix.

Cabinet Office, PPN 006 Technical Standard for Completion of Carbon Reduction Plans (updated 10 July 2025).

GHG Protocol Corporate Standard, Scope 2 Guidance and Corporate Value Chain (Scope 3) Standard.

Science Based Targets initiative guidance on the Corporate Net-Zero Standard, near-term targets and the SME route.

Companies House overview for NEUVIOR Pharmaceuticals Ltd (SC857853).